NEXENTIS TECHNOLOGIES INC. Restricted Cash and Cash Equivalents
NEXENTIS TECHNOLOGIES INC. (NXTS) had Restricted Cash and Cash Equivalents of $22.39 thousand as of 2020-12-31, per its 10-K filed 2021-03-29.
Discontinued › Balance Sheet
us-gaap:RestrictedCashAndCashEquivalents · last filed 2021-03-29
- 2020-12-31: Restricted Cash and Cash Equivalents $22.39K.
- 2019-12-31: Restricted Cash and Cash Equivalents $38.19K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2020-12-31 | $22.39K 10-K · filed 2021-03-29 |
| 2019-12-31 | $38.19K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |